Swiss drug giant Roche ($RHHBY) has happily unveiled data from a Phase IV study that show its treatment Actemra--marketed in Europe as RoActemra--beat adalimumab or Humira in a head-to-heat study involving patients with rheumatoid arthritis. After 24 weeks of treatment, patients on Actemra monotherapy showed steeper drops in disease activity than those who took Abbott Laboratories' ($ABT) blockbuster drug Humira alone, Reuters reported. These results could become important as companies such as Roche and Abbott jockey for their shares of an increasingly crowded market for RA drugs.